Claims
- 1. A method of inhibiting the complement system in a warm-blooded animal which comprises internally administering to said animal an effective complement inhibiting amount of a compound of the formula: ##STR12## wherein R is selected from the group consisting essentially of ##STR13## R.sub.1 is ##STR14## R.sub.2 is hydrogen or --CH.sub.3 ; R.sub.3 is hydrogen, --NO.sub.2, --NH.sub.2, or --CH.sub.3 ;
- R.sub.4 is hydrogen, --NO.sub.2, --NH.sub.2, --CH.sub.3 or ##STR15## and A is hydrogen, alkali metal or alkaline earth with the proviso that each A is identical in the same compound.
- 2. A method according to claim 1 wherein the compound is 4-hydroxy-5-(p-nitrobenzamido)-2,7-naphthalenedisulfonic acid, disodium salt.
- 3. A method according to claim 1 wherein the compound is 4-(p-aminobenzamido)-5-hydroxy-2,7-naphthalenedisulfonic acid, disodium salt.
- 4. A method according to claim 1 wherein the compound is 4-hydroxy-5-(4-nitro-3-toluamido)-2,7-naphthalenedisulfonic acid, disodium salt.
- 5. A method according to claim 1 wherein the compound is 4-(4-amino-m-toluamido)-5-hydroxy-2,7-naphthalenedisulfonic acid, disodium salt.
- 6. A method according to claim 1 wherein the compound is 4-hydroxy-5-(m-nitrobenzamido)-2,7-naphthalenedisulfonic acid, disodium salt.
- 7. A method according to claim 1 wherein the compound is 4-(m-aminobenzamido)-5-hydroxy-2,7-naphthalenedisulfonic acid, disodium salt.
- 8. A method according to claim 1 wherein the compound is 4-hydroxy-5-{m-[3-(3-nitro-p-tolyl)ureido] benzamido}-2,7-naphthalenedisulfonic acid, disodium salt.
- 9. A method according to claim 1 wherein the compound is 4-hydroxy-5-(5-nitro-o-toluamido)-2,7-naphthalenedisulfonic acid, disodium salt.
- 10. A method according to claim 1 wherein the compound is 4-(5-amino-o-toluamido)-5-hydroxy-2,7-naphthalenedisulfonic acid, disodium salt.
- 11. A method according to claim 1 wherein the compound is 4-hydroxy-5-(3-nitro-p-toluamido)-2,7-naphthalenedisulfonic acid, disodium salt.
- 12. A method according to claim 1 wherein the compound is 4-(3-amino-p-toluamido)-5-hydroxy-2,7-naphthalenedisulfonic acid, disodium salt.
- 13. A method according to claim 1 wherein the compound is 5,5'-[ureylenebis(m-phenylenecarbonylimino)]bis [4-hydroxy-2,7-naphthalenedisulfonic acid]tetrasodium salt.
- 14. A method according to claim 1 wherein the compound is 3,3'-[ureylenebis(m-phenylenecarbonylimino)]bis [5-hydroxy-2,7-naphthalenedisulfonic acid]tetrasodium salt.
- 15. A method according to claim 1 wherein the compound is 4-{m-{3-[p-(fluorosulfonyl)phenyl]ureido]benzamido}-5-hydroxy-2,7-naphthalenedisulfonic acid, disodium salt.
- 16. A method according to claim 1 wherein the compound is 4-hydroxy-5-{m-[3-(.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl) ureido]benzamido}-2,7-naphthalenedisulfonic acid, disodium salt.
CROSS-REFERENCE TO RELATED APPLICATION
This application is a continuation-in-part of copending application Ser. No. 684,598, filed May 10, 1976, now U.S. Pat. No. 4,046,805.
US Referenced Citations (6)
Number |
Name |
Date |
Kind |
1218654 |
Heymann et al. |
Mar 1917 |
|
1308071 |
Heymann et al. |
Jul 1919 |
|
1606624 |
Fourneau et al. |
Nov 1926 |
|
1968820 |
Dyson et al. |
Aug 1934 |
|
4018764 |
Bernstein et al. |
Apr 1977 |
|
4046805 |
Bernstein et al. |
Sep 1977 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
684598 |
May 1976 |
|